US EditionPossible Paradigm Shift: Chemo-Free 1L Treatment May Be on the Way for Older and Unfit DLBCL Patients
Summary by medicinsketidsskrifter.dk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
HEMATOLOGY JOURNAL New treatment combination can save lives in patients with aggressive lymphoma Older and unfit patients with diffuse large B-cell lymphoma (DLBCL) respond well to treatment with rituximab, Polivy (polatuzumab vedotin) and Columvi (glofitamab) in first line, and the combination is generally well tolerated. This is a growing patient group for which we currently lack effective offers, and this suggests that they may benefit from c…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
